tbuckley/cabot-search huggingface dataset:
Abstract 1229: Neoadjuvant therapy alters collagen architecture of pancreatic cancer
Authors: Kosei Nakajima, Yoshinori Ino, Sotoshi Nara, Toshimitsu Iwasaki, Nobuyoshi Hiraoka
Journal: Cancer Research (2019)

Abstract Treatment of pancreatic cancer remains clinically challenging and requires the novel therapeutic interventions to improve patient outcome. Neoadjuvant therapy i.e. preoperative treatments comprising chemotherapeutic agents with/without radiation offers down-staging and improvement of surgical resectability. Here, we report that neoadjuvant therapy alters collagen architecture of pancreatic cancer. Transcriptomic profiles of type 1 to type 28 collagens depicted changes of collagen composition due to neoadjuvant therapy. Immunohistochemically, the expressed area of collagen type 1, 3, 4, and 5 were significantly reduced post treatment. The bioinformatic approaches provided a comprehensive insight into treatment-induced matrix remodeling, which showed that Ephrin-A signaling and Ephrin-A5 appeared as a highly possible pathway and a crucial ligand. Ephrin-A5 co-localized with alpha-SMA(+) cancer-associated fibroblasts, whereby Ephrin-A5 have been implicated to synthesize collagens. The Ephrin-A5 positive cells significantly reduced after neoadjuvant therapy, also inversely correlated with tumor shrinkage rate. Using primary culture cells of cancer-associated fibroblasts, experimental exposure of radiation and chemotherapeutic agents suppressed the proliferation of cancer-associated fibroblasts, collagen synthesis and Ephrin-A5 expression. Thus, our studies demonstrate that neoadjuvant therapy down-regulates Ephrin-A5 expression, leading to a change of extracellular matrix structure. It should be a clinical concern of surgical handling when following resection. Note: This abstract was not presented at the meeting. Citation Format: Kosei Nakajima, Yoshinori Ino, Sotoshi Nara, Toshimitsu Iwasaki, Nobuyoshi Hiraoka. Neoadjuvant therapy alters collagen architecture of pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1229.
Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex
Authors: S MOTEKI
Journal: Hepatology (1996)

Five different target mitochondrial autoantigens recognized by sera from patients with primary biliary cirrhosis (PBC) have been identified as subunits of the following 2-oxo acid dehydrogenase complexes: the pyruvate dehydrogenase complex (PDC), the branched chain 2-oxo acid dehydrogenase complex (BCOADC), and the 2-oxoglutarate dehydrogenase complex (OGDC). Unlike the E2 subunits of PDC (PDC-E2) and BCOADC (BCOADC-E2), the E2 subunits of OGDC (OGDC-E2) reactivity of PBC sera and the reactive epitope of OGDC-D2 have not hitherto been studied in detail. In this report, we took advantage of a recombinant fusion protein for OGDC-E2 to address these issues. Eighty of 268 (29.9%) PBC patient sera but none of the 45 controls reacted with recombinant OGDC-E2. The recombinant OGDC-E2 was judged to express the immunodominant epitope, because when sera from patients with PBC were preabsorbed with the recombinant fusion protein, such sera were depleted of reactivity against 48 kD OGDC-E2 when probed on beef heart mitochondria (BHM) but retained reactivity toward PDC-E2 and/or BCOADC-E2. Furthermore, affinity-purified PBC sera against recombinant OGDC-E2 reacted only with native OGDC-E2 and not with any other enzyme components of the 2-oxo acid dehydrogenase complex. Antimitochondrial autoantibodies (AMA) against OGDC-E2 included immunoglobulin (Ig)G2, IgG3 and IgM and the relative titers were as follows: IgG2 > IgG3 > IgM. Finally, using overlapping recombinant polypeptides, it was determined that a minimum of 81 amino acids (residues 67-147) corresponding to the lipoyl domain of OGDC-E2 are necessary for reactivity, suggesting that a conformational autoepitope is recognized by AMA. These data suggest that each of the 2-oxo acid dehydrogenase enzymes has distinct antigenicity despite their similarities in structure and function. The availability of recombinant OGDC-E2 autoantigen will allow the design of additional studies to further our understanding of the role of mitochondrial autoantigens in the pathogenesis of PBC.
THE MILWAUKEE MEETING.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of sentinel lymph node biopsy on staging of early cervical cancer: Results of a prospective, multicenter study
Authors: F. Lecuru, A. Bats, P. Mathevet, D. Querleu, E. Leblanc, P. Morice, E. Darai, H. Marret, C. Collin, G. Chatellier, F. Gilaizeau
Journal: Journal of Clinical Oncology (2009)

CRA5506 Background: 10% to 15% of patients with pN0 early cervical cancer experience recurrences. This may be related either to nodes missed by the dissection or located outside the dissection field or to failed diagnosis of node metastases. The objective of this study was to measure the benefits from sentinel node (SN) detection in terms of nodes collected from unusual territories and of detected micrometastases and isolated tumor cells (ITCs). Methods: 145 patients who had stage Ia1-Ib1 epidermoid cancer or adenocarcinoma or adenosquamous cancer were included in a multicenter study (January 2005 - June 2007). Noninclusion criteria were age&lt;18 years, pregnancy, and previous treatment. SNs were identified by combined technetium and blue-dye labeling in the pelvic and para-aortic territories. Slices were cut 200 μm apart. At each level, HES staining and labeling with anti-cytokeratin antibodies (AE1-AE3) were performed. SNs in an unusual territory were defined as SNs outside the ilio-obturator region. ITC was defined as size &lt;0.2 mm, micrometastasis as size 0.2 to 2mm, and macrometastases as size &gt;2 mm. The study was funded by the French National Institute of Cancer and reviewed by an IRB. Results: 17 patients were excluded for major protocol deviations, leaving 128 patients for the per protocol analysis. One or more SNs were detected in 98.4% of patients (95%CI, 94.4 to 99.9%). The 430 detected SNs were located as follows: external iliac, 80.5 %; common iliac, 8.6%; presacral and paraaortic, 5.5%; and parametrial, 4.9 %. SN detection identified at least one SN in an unusual territory in 48/128 (37.5%) patients. There were 26 positive SNs in 21(16.4%) patients of whom 8 (38%) had macrometastases, 7 (33%) micrometastases, and 6 (29%) ITCs. Of these 26 nodes, 7 (27%) were detected only by immunohistochemistry (6/128 patients: 4.6%). There was no false-negative No node metastases were found in 104/128 (81.2%) patients. Conclusions: SN detection supplied additional information in 39.8% of patients (51/128), either showing that drainage occurred via unusual pathways or detecting cancer spread via immunohistochemistry. Node dissection could have been avoided in the 104/128 patients with negative nodes, potentially decreasing treatment-associated morbidity. No significant financial relationships to disclose.
Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia
Authors: M. I. Evans
Journal: JAMA (1985)

21-Hydroxylase deficiency results in congenital adrenal hyperplasia and leads to masculinization of the external genitalia of affected females. This complication could be avoided if fetal adrenal gland function were suppressed. A woman with mild 21-hydroxylase deficiency whose previous female child had classic congenital adrenal hyperplasia with masculinization was given dexamethasone beginning at the tenth week of gestation. Maternal estriol and cortisol values indicated rapid and sustained fetal and maternal adrenal gland suppression. At 39 weeks' gestation, the patient was spontaneously delivered of a female neonate with normal external genitalia. Postnatal tests indicated the infant was a single heterozygote for 21-hydroxylase deficiency. This study demonstrates prolonged suppression of the fetal adrenal gland with dexamethasone and suggests it might prevent abnormal masculinization in fetuses with severe congenital adrenal hyperplasia. (<i>JAMA</i>1985;253:1015-1020)
Update: Availability of Sulfadiazine—United States
Journal: JAMA (1994)

Sulfadiazine is a sulfa drug commonly used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome (AIDS) and newborns with congenital infections. In December 1992, CDC reported that the domestic manufacturer of sulfadiazine had ceased production in October 1992 and that no large inventories of the drug were available from major distributors (1). On February 8, CDC obtained permission from the Food and Drug Administration (FDA) to proceed with an "Investigational New Drug" (IND) application protocol under which sulfadiazine may be imported and made available to physicians until a domestic commercial source is re-established.
Mithramycin therapy in disseminated germinal testicular cancer
Authors: N. W. Ream
Journal: JAMA (1968)

Mithramycin, an antibiotic, was used in the treatment of 30 patients with disseminated germinal testicular cancer. The antitumor effect of mithramycin was evaluable in 26. Nine patients experienced an objective antitumor response, which has been complete in two. The major responses occurred in patients with embryonal carcinoma with pulmonary metastases. No significant response was observed in patients with advanced retroperitoneal or hepatic metastases from embryonal carcinoma or in the six patients with teratocarcinoma. The toxicity of mithramycin encountered in this investigation does not preclude employing this agent as a primary treatment of metastases from embryonal carcinoma of the testis.
The Office Treatment of Hemorrhoids, Fistula, etc., without operation, together with remarks on the relation of diseases of the rectum to other diseases in both sexes, but especially in women, and the abuse of the operation of colostomy.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Working Hours of Junior Staff
Authors: G. E. Adkins, P. Beasley, G. B. Jones, T. L. Bradbeer, F. S. W. Brimblecombe, G. L. Cantrell, B. Chudecki, D. Collyer, A. J. Daly, F. Durbin, A. J. Evans, N. Gardner, M. George, J. L. Griffith, L. Haas, R. Hadden, G. H. Hal, R. J. Hart, I. A. Horton, M. L. James, D. Jefferiss, R. S. W. Ling, D. Mattingly, B. Moore, G. D. Morrison, R. LE. Orme, C. R. H. Penn, W. Rich, C. Schwerdt, P. Scott, C. Shaldon, J. H. Simpson, J. R. Simpson, J. T. Smyth, R. Y. Stevenson, J. Watkins, K. Vowles
Journal: BMJ (1974)
A Nonlinear Association of Serum Cholesterol Level with Incident Coronary Heart Disease in Elderly Men
Authors: Beatriz L Rodriguez, Robert D Abbott, Kamal H Masaki, Irwin J Schatz, Randi Chen, Katsuhiko Yano, Jess D Curb
Journal: Circulation (2001)

P62 Increased serum cholesterol has been found to be a direct risk factor for coronary heart disease (CHD) in middle aged individuals in epidemiologic follow-up studies. However, this relationship has not been consistently reproduced in elderly populations. From 1991-93, 2424 elderly (71-93 years old) Japanese American men from the Honolulu Heart Program cohort, who did not have prevalent CHD and who were not on cholesterol lowering drugs, were examined. The subsequent 6-year follow-up provided an opportunity to closely examine the relationship between their baseline cholesterol and their incidence of CHD as determined by surveillance and a physician panel review. The study revealed a significant non-linear association of the baseline cholesterol with the incidence of CHD (p=0.033). Among the 1524 elderly men with cholesterol values below 200mg/dl the age adjusted CHD rate decreased as the mean cholesterol level increased. In those with cholesterol levels of greater than or equal to 200mg/dl (900) the age adjusted CHD rates increased with increasing level of cholesterol. The lowest CHD rates were seen in men with cholesterol levels between 200 and 219 mg/dl. Multivariate adjustment for other know risk factors (BMI, smoking, hypertension, diabetes, and HDL), decreased the strength of this non-linear relationship but it remained significant (p=0.049). A measure of frailty (10% weight loss since an exam 20 years before) further reduced the strength of the cholesterol relationship slightly but did so by reducing the magnitude of the cholesterol/CHD relationship in both those higher cholesterol (positive relationship) and those with lower cholesterol (negative relationship). Thus it is unlikely that frailty can fully explain the reverse cholesterol/CHD relationship seen in those with lower cholesterol levels. In this study the majority of men already had cholesterol levels below the standard cutpoint of 200mg/dl and had the opposite pattern of risk as elderly men with cholesterols above that cutpoint. This would indicate that further data is needed before recommending lowering of cholesterol to levels below 200mg/dl in older individuals.
The inaccessibility of advance directives on transfer from ambulatory to acute care settings
Authors: R. S. Morrison
Journal: JAMA (1995)

<h3>Objective.</h3> —To investigate the accessibility of patients' previously executed advance directives during an acute hospitalization. <h3>Design.</h3> —Retrospective chart review. <h3>Setting.</h3> —A large metropolitan teaching hospital, a 514-bed skilled nursing facility, a geriatrics ambulatory care clinic, and a geriatrics group practice office. <h3>Patients.</h3> —One hundred fourteen geriatric patients who had previously executed an advance directive. <h3>Main Outcome Measures.</h3> —The medical records of 180 admissions over 3 years, 1991 through 1993, were reviewed for documentation of patients' advance directive status. <h3>Results.</h3> —Twenty-six percent of patients who had previously executed advance directives had their directives recognized during their hospitalization. Of the subgroup of patients who were judged not to have the capacity to make medical decisions during their admissions, 26% (14/53) had their directives recognized. When the advance directive was recognized, it appeared to influence treatment decisions in 12 (86%) of 14 cases. <h3>Conclusions.</h3> —Previously executed advance directives are not accessible when patients are admitted to hospitals for acute illness. When such directives are recognized, they are used to influence medical treatment decisions. Further research is needed to define and overcome barriers to this inaccessibility. (<i>JAMA</i>. 1995;274:478-482)
International Abstracts
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the National Institutes of Health
Authors: William Raub
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Physician
Authors: Michael H. M. Dykes
Journal: JAMA (1977)

MY USE of the word "information" instead of "knowledge" is intended to stress that the physician often has to act on evidence that cannot be classified as "scientific knowledge." My remarks will be based on two premises. First, although "the practice of medicine today is clearly a cooperative venture that relies on the expertise of many individuals in addition to that of the physician,"<sup>1</sup>when a physician is granted a license to practice medicine, he is charged with the ultimate responsibility for deciding what diagnostic procedures and items of therapy will or will not be provided. Second, this is true and will continue to be true whether the physician is in private practice, institutional practice, or government service. Ingelfinger<sup>2</sup>has succinctly defined the good physician as one who practices by "the exercise of well-based and independent clinical judgment." I interpret this as suggesting that when a physician plans
Group A streptococcal sepsis and arthritis. Origin from an intrauterine device
Authors: J. D. Brosseau
Journal: JAMA (1977)

INFECTION is a recognized risk of the intrauterine device (IUD).<sup>1</sup>The causative organisms are usually vaginal or colonic flora or<i>Neisseria gonorrhoeae</i>, and the infections tend to be localized to the pelvis.<sup>2</sup>We report a case of group A streptococcal septicemia with monoarticular arthritis, originating from an infected IUD. Our evidence suggests that the infection was transmitted to the patient through sexual foreplay. <h3>Report of a Case</h3> A 28-year-old woman had fever and chills followed by headache, nausea, and vomiting. After three days she was awakened at night by severe pain in her right shoulder and wrist. During the next two days, this pain became worse and she sought medical attention. Her past medical history was unremarkable. A Lippe's loop was inserted two years earlier following her second normal pregnancy and delivery. Three weeks before her present illness, sore throat and cellulitis of several fingers on both hands
THE RELATION OF THE SPINAL CORD TO THE SPONTANEOUS LIBERATION OF EPINEPHRIN FROM THE ADRENALS
Authors: G. N. Stewart, J. M. Rogoff
Journal: The Journal of Experimental Medicine (1917)

On page 616, Vol. XXVI, No. 5, November 1, 1917, foot-note 2, for Marine, D., and Rogoff, J. M., J. Pharm. and Exp. Therap., 1916-17, ix, 1, read Stewart, G. N., and Rogoff, J. M., J. Pharm. and Exp. Therap., 1917, x, 1. On page 627, foot-note 4, for Stewart and Rogoff, J. Pharm. and Exp. Therap., 1916-17, ix, 479, read Stewart and Rogoff, J. Pharm. and Exp. Therap., 1916, viii, 479.
Catheter ablation of atrial fibrillation using a non-fluoroscopic system
Authors: C. Pappone, F. Lamberti, M. Rillo, G. Vicedomini, A. Conversano, M.L. Loricchio, P. Mazzone, S.B. Haim, S. Bianchi, S.L. Chierchia
Journal: Journal of the American College of Cardiology (1998)